Holt B G, White J J, Kuthiala A, Fall P, Szerlip H M
Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA.
Clin Nephrol. 2008 Jan;69(1):40-6. doi: 10.5414/cnp69040.
Acute kidney injury (AKI) commonly occurs in critically ill patients with sepsis and is associated with poor outcomes. Unfortunately, the ideal mode of renal replacement therapy remains unknown. Because both higher doses of dialysis and hemofiltration have been associated with improved survival, we postulated that adding hemofiltration to the diffusive clearance achieved by sustained low-efficiency daily dialysis (SLEDD-f) would provide a survival advantage over SLEDD.
From December 2003 to October 2005, we retrospectively analyzed all patients with multisystem organ failure, vasopressor-dependent hypotension and oliguric acute kidney failure secondary to nonoperative sepsis who were treated with renal replacement therapy (RRT). After exclusionary criteria were applied, 8 patients received SLEDD-f and 13 patients received SLEDD. All treatments were for 8 - 16 h/day. SLEDD-f was continued until vasopressors were reduced to a minimal dose. Outcomes were mortality and recovery of renal function at 30 days after initiation of RRT. APACHE- II scores were calculated at the time of dialysis initiation to predict mortality.
Despite higher APACHE II scores, 30-day survival was 100% in the SLEDD-f group and 38% in the SLEDD group. Furthermore, most of the SLEDD-f patients were able to have vasopressors weaned quickly and all patients in the SLEDD-f group recovered significant renal function to allow discontinuation of RRT.
While the optimal treatment remains unknown, this small study raises the possibility that SLEDD-f offers a survival advantage and increases the chance of renal recovery while decreasing the need for vasopressors. A large randomized trial comparing SLEDD-f with other forms of renal replacement therapy is needed.
急性肾损伤(AKI)常见于脓毒症危重症患者,且与不良预后相关。遗憾的是,理想的肾脏替代治疗模式仍不明确。由于更高剂量的透析和血液滤过均与生存率提高相关,我们推测,在持续低效每日透析(SLEDD-f)实现的弥散清除基础上增加血液滤过,相较于SLEDD可带来生存优势。
2003年12月至2005年10月,我们回顾性分析了所有接受肾脏替代治疗(RRT)的多系统器官衰竭、因非手术性脓毒症导致血管活性药物依赖型低血压及少尿性急性肾衰竭患者。应用排除标准后,8例患者接受SLEDD-f治疗,13例患者接受SLEDD治疗。所有治疗均为每天8 - 16小时。SLEDD-f持续进行直至血管活性药物剂量降至最小。观察指标为RRT开始后30天的死亡率和肾功能恢复情况。透析开始时计算急性生理与慢性健康状况评分系统(APACHE-II)分数以预测死亡率。
尽管SLEDD-f组APACHE II分数更高,但该组30天生存率为100%,而SLEDD组为38%。此外,大多数接受SLEDD-f治疗的患者能够迅速停用血管活性药物,且SLEDD-f组所有患者的肾功能均有显著恢复,从而得以停止RRT治疗。
虽然最佳治疗方案仍不明确,但这项小型研究提示,SLEDD-f可能具有生存优势,可增加肾功能恢复的机会,同时减少对血管活性药物的需求。需要开展一项大型随机试验,比较SLEDD-f与其他形式的肾脏替代治疗。